TY - JOUR
T1 - No association between common chemokine and chemokine receptor gene variants and prostate cancer risk
AU - Petersen, Desiree C.
AU - Severi, Gianluca
AU - Hoang, Hoa N.
AU - Padilla, Emma J.D.
AU - Southey, Melissa C.
AU - English, Dallas R.
AU - Hopper, John L.
AU - Giles, Graham G.
AU - Hayes, Vanessa M.
PY - 2008/12/1
Y1 - 2008/12/1
N2 - There is growing evidence that inflammation and infection play important roles in the etiology of prostate cancer. As the chemokine network is directly involved in inflammation and infectious diseases, we tested for an association between six common putative functional variants and prostate cancer risk using an Australian case-control study. We measured CCL5 -403G>A, CXCL12 +801G>A, CCR2V64I (G>A), CCR5Δ32, CX3CR1V249I (G>A), and CX3CR1T280M (C>T) for 815 cases and 738 controls. Of these, only CXCL12 +801G>A has previously been tested and found to be associated withprostate cancer risk. We found no significant associations withprostate cancer risk (all P > 0.4). All per allele odds ratios ranged from 0.96 (95% confidence intervals, 0.80-1.16) to 1.06 (95% confidence intervals, 0.90-1.23). This suggests that these common chemokine and chemokine receptor variants do not play a major, if any, role in susceptibility to prostate cancer.
AB - There is growing evidence that inflammation and infection play important roles in the etiology of prostate cancer. As the chemokine network is directly involved in inflammation and infectious diseases, we tested for an association between six common putative functional variants and prostate cancer risk using an Australian case-control study. We measured CCL5 -403G>A, CXCL12 +801G>A, CCR2V64I (G>A), CCR5Δ32, CX3CR1V249I (G>A), and CX3CR1T280M (C>T) for 815 cases and 738 controls. Of these, only CXCL12 +801G>A has previously been tested and found to be associated withprostate cancer risk. We found no significant associations withprostate cancer risk (all P > 0.4). All per allele odds ratios ranged from 0.96 (95% confidence intervals, 0.80-1.16) to 1.06 (95% confidence intervals, 0.90-1.23). This suggests that these common chemokine and chemokine receptor variants do not play a major, if any, role in susceptibility to prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=57449087871&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-08-0896
DO - 10.1158/1055-9965.EPI-08-0896
M3 - Article
C2 - 19064579
AN - SCOPUS:57449087871
SN - 1055-9965
VL - 17
SP - 3615
EP - 3617
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 12
ER -